BiVictriX receives Bionow Investment Deal of the Year Award
BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, is delighted to announce it won the Investment Deal of the Year Award at Bionow’s 20th annual awards for its IPO on AIM in 2021.
Tiffany Thorn, Chief Executive of BiVictriX, commented:“The entire team at BiVictriX is delighted to have received this award. It recognises the incredible commitment of our scientists, advisors and directors to achieving our goal of developing novel oncology treatments where there is serious unmet medical need.”
Bionow is a not for profit membership organisation that advocates for the biomedical, pharma and life sciences in the North of England, offering businesses all the tools they need to excel in the industry and supporting the innovative life science industry of the North. The 20th Bionow Annual Awards are a recognition of the tireless work being done by the life science sector and a celebration of innovation and enterprise.